Table 3.
Main findings and characteristics of the admixture mapping studies of AEs conducted from 15th November, 2018 to 1st October, 2022.
| rsID (Gene) Chromosomal band |
Subjects | Phenotype | EA | OR (95%CI) | P | PMID [reference] |
|---|---|---|---|---|---|---|
|
| ||||||
| rs1144986 (C5orf46) 5q32 |
Patients with asthma. Discovery: 625 Mexican Americans. R1: 1,124 Puerto Ricans R2: 1,001 African Americans, 1,250 Singaporeans, and 941 Europeans. |
ER/Hosp/OCS | G | Discovery: 0.43 (0.28, 0.66) R1: 0.79 (0.62, 1.00) |
9.45×10−5; 4.94×10−2; NS |
36180068 [92] |
|
| ||||||
| rs5752429 (TPST2) 2q12.1 |
Discovery: 266 adolescents/adults of African-descent ancestry Replication: 222 African Americans |
Discovery: Better response to 5xICS vs 2.5xICS Replication: ER/Hosp/OCS despite high ICS use |
A | Discovery: 0.21 (0.09, 0.52)* Replication: 2.28 (1.33, 3.90) |
6×10−4; 0.003 |
34762840 [93] |
| rs73399224 (RNFT2) 12q24.22 |
Discovery: 250 children of African-descent ancestry Replication: 379 African Americans |
Discovery: Better response to 5xICS vs 100 μg fluticasone plus salmeterol Replication: ER/Hosp/OCS despite ICS use |
G | Discovery: 0.17 (0.07, 0.42)* Replication: 1.97 (1.07, 3.64) |
8.0×10−5; 0.03 |
|